• Active Ingredient: Alendronate
  • 70 mg, 35 mg, 5 mg
Buy Now

What is Lozostun?

The active ingredient of Lozostun brand is alendronate. Alendronate is a bisphosphonate (bis FOS fo nayt) medicine that slows bone loss while increasing bone mass, which may prevent bone fractures. Alendronate sodium is a white, crystalline, nonhygroscopic powder. It is soluble in water, very slightly soluble in alcohol, and practically insoluble in chloroform. Alendronate sodium tablets, USP, for oral administration contain 45.68 mg or 91.37 mg of Alendronate monosodium salt trihydrate, which is the molar equivalent of 35 mg and 70 mg, respectively, of free acid, and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. This product meets USP Dissolution Test 2.

Used for

Lozostun is used to treat diseases such as: Aseptic Necrosis, Osteoporosis, Paget's Disease, Prevention of Osteoporosis.

Side Effect

Possible side effects of Lozostun include: difficulty with moving; difficulty with breathing; tingling of the hands or feet; rapid weight gain; heartburn; chills; Skin rash.

How to Buy Lozostun online?

To purchase Lozostun online - simply click on the "Buy Now" button from the top and follow on to our shop. Payment and Order takes a couple of minutes, and all steps are evident. We don't take a medical prescription plus we have many procedures of payment. With all the details of rapid delivery and confidentiality, then you may read on the relevant pages on the hyperlinks from the top menu.

Related Medications


Prodexin 500mg, 250mg


More info


Fematab 2mg, 1mg


More info


Flamquit 100mg


More info


Etol 400mg, 300mg, 200mg


More info


In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of Lozostun greater than 10 mg and aspirin-containing products.

Q: My gynecologist has me on Fosamax Plus D for osteopenia. Can I take calcium with vitamin D? I know that the calcium needs the vitamin D to be absorbed. Is it possible to take too much vitamin D? What amount would you recommend?

A: Fosamax Plus D is a prescription medicine that contains Lozostun sodium and vitamin D3 (cholecalciferol) as the active ingredients. Fosamax Plus D provides a week's worth of vitamin D3 (2800 IU). The Daily Value is 400 IU. Fosamax Plus D is used for the treatment of osteoporosis (thinning of bone) in women after menopause. It reduces the chance of having a hip or spinal fracture (break). Treatment to increase bone mass in men with osteoporosis. Fosamax Plus D (Lozostun cholecalciferol), a single once weekly tablet containing 70 mg Fosamax (Lozostun) and 2,800 IU vitamin D3, representing seven days worth of 400 IU of vitamin D. (The recommended intake of vitamin D is 400 to 800 IU daily). Maintaining adequate levels of vitamin D is necessary for the development of strong bones because it helps increase the intestinal absorption of calcium. Vitamin D insufficiency is associated with reduced calcium absorption, bone loss and increased risk of fracture. Patients at increased risk for vitamin D insufficiency (e.g., those who are nursing-home bound, chronically ill, over the age of 70 years) and with gastrointestinal malabsorption syndromes should receive vitamin D supplementation in addition to that provided in Fosamax Plus D. For more detailed information, consult with your physician or pharmacist for guidance based on your specific condition and current medications. Shereen A. Gharbia, PharmD

Q: I have pseudogout and take Fosamax. Is that wrong to take because of the extra calcium?

A: Fosamax (Lozostun) is classified as a bisphosphonate derivative. Fosamax is approved for the treatment of osteoporosis in women that are postmenopausal, treatment of osteoporosis in males, the treatment of Paget's disease, and the treatment of glucocorticoid induced osteoporosis in men and women. Fosamax works in the body to inhibit bone resorption by affecting the actions of osteoclasts or the precursors to osteoclasts. Bone resorption is defined as the process in the body that occurs when osteoclasts break down bones. This process releases the minerals, such as calcium, from the bones into the bloodstream. Therefore, Fosamax decreases bone resorption resulting in an increase in the bone mineral density. As a result of the way that Fosamax works, blood levels of calcium should be decreased instead of increased because, theoretically, less calcium is released from the bones into the blood. In fact, hypocalcemia or low levels of calcium in the blood is one of the listed possible side effects associated with treatment with Fosamax. This is not the only associated side effect of the medication. Pseudogout is defined as a sudden swelling of a joint, or joints, that results from a form of arthritis. Pseudogout occurs when crystals of calcium pyrophosphate dihydrate (CPPD) develop around or in the joints. The result is painful inflammation of the affected area. A review of medical literature discovered extremely rare reports of patients that were taking Fosamax developing pseudogout. It is stated, in a clinical study, that bisphosphonates are similiar in structure to pyrophosphate. However, the mechanism in which taking bisphosphonate medications could lead to deposits of CPPD crystals in and around the joints is unknown. The author of the study states that there are very few cases of this occuring considering the vast amount of patients that are treated with bisphosphonates. It appears that additional studies need to be performed to fully understand this possible connection. Talk to your physician regarding the questions and concerns that you have regarding your medical conditions and your medications. For more specific information, consult with your doctor or pharmacist for guidance based on your health status and current medications, particularly before taking any action. Jen Marsico, RPh

Lozostun Description

Lozostun sodium is a bisphosphonate that acts as a specific inhibitor of osteoclast­-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.

Lozostun sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate.

The empirical formula of Lozostun sodium is C 4 H 12 NNaO 7 P 2 •3H 2 O and its formula weight is 325.12. The structural formula is:

How is this medicine (Lozostun Tablets) best taken?

Use this medicine (Lozostun tablets) as ordered by your doctor. Read all information given to you. Follow all instructions closely.

  • Take on an empty stomach before breakfast.
  • Take at least 30 minutes before the first food, drink, or drugs of the day.
  • Do not lie down for at least 30 minutes after taking this medicine (Lozostun tablets).
  • Keep taking this medicine (Lozostun tablets) as you have been told by your doctor or other health care provider, even if you feel well.
  • To gain the most benefit, do not miss doses.
  • Take with a full glass of water.
  • Take with plain water only. Avoid taking with mineral water, milk, or other drinks.
  • Swallow whole. Do not chew, break, or crush.

What do I do if I miss a dose?

  • Do not take it later in the day.
  • Take the missed dose on the next morning after you think about it and then go back to your normal time.
  • Do not take 2 doses on the same day.

What is Lozostun (Binosto, Fosamax)?

Lozostun is a bisphosphonate (bis FOS fo nayt) medicine that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures.

Lozostun is used to treat osteoporosis caused by menopause, steroid use, or gonadal failure. This medicine is for use when you have a high risk of bone fracture due to osteoporosis.

Lozostun is also used to treat Paget's disease of bone.

Lozostun may also be used for purposes not listed in this medication guide.

Q: Is it safe to take Fosamax over a long period of time? What are the side effects?

A: Fosamax (Lozostun) is in a drug class called bisphosphonates. Fosamax is used to prevent and treat osteoporosis (thinning and weakening of bones which may cause them to break easily) in women who have been through menopause. Fosamax is also used to treat osteoporosis in men. Additionally, Fosamax is used to treat osteoporosis in women and men who are taking corticosteroids, which are medicines that have the potential to cause osteoporosis. Also, Fosamax is used to treat Paget's disease of bone, which is a disorder where bones are soft, weak, and may be deformed, cause pain, and break easily. Fosamax works by preventing the breakdown of bone and increasing bone density (thickness of bone). Fosamax should be taken with a glass of water and no other food or drink should be consumed for 30 minutes. Also, do not lie down after taking Fosamax, it is important to remain up straight for at least 30 minutes after taking Fosamax. According to National Osteoporosis Foundation (NOF), Fosamax lessens bone loss and increases bone density. In addition, according to NOF, Fosamax reduces the risk of spine, hip and other fractures by approximately 50% over 2 to 4 years. Some of the common side effects experienced with Fosamax include: abdominal pain, nausea, acid reflux, gas, constipation and headache. Severe bone/joint/muscle pain has been reported with the use of Fosamax. Some people experienced this pain within 1 day to several months after starting Fosamax. The pain usually subsides with discontinuation of the medication. Some people will have the pain reoccur if they are rechallenged with Fosamax or another bisphosphonate. One of the rare side effects of Fosamax is called osteonecrosis of the jaw (ONJ). ONJ may occur spontaneously after dental procedures or tooth extractions. There may be delayed healing after dental procedures and the bone of the jaw becomes exposed. Symptoms of ONJ may include: pain, swelling, infection, poor healing, loosening of teeth, or numbness of the jaw. According to the National Osteoporosis Foundation, it is important for patients taking Fosamax, or similar medications, to maintain good oral hygiene and have regular dental visits. Fosamax may also cause problems with the esophagus. The esophagus is the tube that connects the mouth to the stomach. Fosamax can cause irritation and erosion to the esophagus, especially if the dosing directions are not followed. Low blood calcium (hypocalcemia) has been reported with the use of Fosamax. Before therapy is started, calcium levels should be checked and it is important for the patient to have adequate calcium and vitamin D supplementation during therapy. This is not a complete list of the side effects associated with Fosamax. Please consult with your doctor about the long term use of Fosamax and the duration of treatment appropriate for you. For more specific information, consult with your doctor for guidance based on your health status and current medications, particularly before taking any action. Kristen Dore, PharmD

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Lozostun sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body as a Whole: hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with Lozostun sodium, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema.

Gastrointestinal: esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe and with complications, have also been reported .

Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported .

Musculoskeletal: bone, joint, and/or muscle pain, occasionally severe, and incapacitating ; joint swelling; low-energy femoral shaft and subtrochanteric fractures .

Nervous System: dizziness and vertigo.

Pulmonary: acute asthma exacerbations.

Skin: rash (occasionally with photosensitivity), pruritus, alopecia, severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.

Special Senses: uveitis, scleritis or episcleritis. Cholesteatoma of the external auditory canal (focal osteonecrosis).

Pediatric Use

Lozostun sodium is not indicated for use in pediatric patients.

The safety and efficacy of Lozostun sodium were examined in a randomized, double-blind, placebo-controlled two-year study of 139 pediatric patients, aged 4 to 18 years, with severe osteogenesis imperfecta (OI). One-hundred-and-nine patients were randomized to 5 mg Lozostun daily (weight less than 40 kg) or 10 mg Lozostun daily (weight greater than or equal to 40 kg) and 30 patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was -4.5. The mean change in lumbar spine BMD Z-score from baseline to Month 24 was 1.3 in the Lozostun sodium-treated patients and 0.1 in the placebo-treated patients. Treatment with Lozostun sodium did not reduce the risk of fracture. Sixteen percent of the Lozostun sodium patients who sustained a radiologically-confirmed fracture by Month 12 of the study had delayed fracture healing (callus remodeling) or fracture non-union when assessed radiographically at Month 24 compared with 9% of the placebo-treated patients. In Lozostun sodium-treated patients, bone histomorphometry data obtained at Month 24 demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between the Lozostun sodium and placebo groups in reduction of bone pain. The oral bioavailability in children was similar to that observed in adults.

The overall safety profile of Lozostun sodium in osteogenesis imperfecta patients treated for up to 24 months was generally similar to that of adults with osteoporosis treated with Lozostun sodium. However, there was an increased occurrence of vomiting in osteogenesis imperfecta patients treated with Lozostun sodium compared to placebo. During the 24-month treatment period, vomiting was observed in 32 of 109 (29.4%) patients treated with Lozostun sodium and 3 of 30 (10%) patients treated with placebo.

In a pharmacokinetic study, 6 of 24 pediatric osteogenesis imperfecta patients who received a single oral dose of Lozostun 35 mg or 70 mg developed fever, flu-like symptoms, and/or mild lymphocytopenia within 24 to 48 hours after administration. These events, lasting no more than 2 to 3 days and responding to acetaminophen, are consistent with an acute-phase response that has been reported in patients receiving bisphosphonates, including Lozostun sodium.

* Number evaluable for vertebral fractures: Lozostun sodium, n=984; placebo, n=966 † p ‡ p=0.007, § p ¶ p Figure 1: Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT (patients with radiographic vertebral fracture at baseline)

If you experience side effects

It's perfectly natural to be concerned by side effects although, in most cases, they do pass.

The best thing to do is speak to your doctor or pharmacist. They can assess if there's a better treatment for you. They can also help you work out whether Lozostun is causing the symptoms, or if something else is the cause, such as another medication.

How should I take Lozostun (Binosto, Fosamax)?

Lozostun is taken either once daily or once per week. Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.

Take Lozostun first thing in the morning, at least 30 minutes before you eat or drink anything or take any other medicine. If you take Lozostun only once per week, take it on the same day each week and always first thing in the morning.

Take with a full glass (6 to 8 ounces) of plain water. Do not use coffee, tea, soda, juice, or mineral water. Do not eat or drink anything other than plain water.

Measure liquid medicine with the dosing syringe provided, or with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one.

Do not crush, chew, or suck on an Lozostun regular tablet. Swallow it whole.

Dissolve the effervescent tablet in at least 4 ounces of water (at room temperature, not hot or cold). Let the tablet dissolve for 5 minutes. Stir this mixture for 10 seconds and drink all of it right away. Add a little more water to the glass, swirl gently and drink right away.

For at least 30 minutes after taking Lozostun:

  • Do not lie down or recline.
  • Do not take any other medicine including vitamins, calcium, or antacids.

Pay special attention to your dental hygiene while taking Lozostun. Brush and floss your teeth regularly. If you need to have any dental work (especially surgery), tell the dentist ahead of time that you are using Lozostun.

Lozostun is only part of a complete program of treatment that may also include diet changes, exercise, bone mineral density testing, and taking calcium and vitamin supplements. Follow your doctor's instructions very closely.

Store at room temperature away from moisture and heat. Keep unused effervescent tablets in the foil blister pack.

Your doctor will determine how long to treat you with this medicine. Lozostun is often given for only 3 to 5 years.

What should I discuss with my healthcare provider before taking Lozostun (Binosto, Fosamax)?

You should not take Lozostun if you are allergic to it, or if you have:

  • low levels of calcium in your blood (hypocalcemia); or
  • problems with the muscles in your esophagus (the tube that connects your mouth and stomach).

Do not take Lozostun if you cannot sit upright or stand for at least 30 minutes. Lozostun can cause serious problems in the stomach or esophagus. You must stay upright for at least 30 minutes after taking this medicine.

To make sure Lozostun is safe for you, tell your doctor if you have ever had:

  • trouble swallowing;
  • problems with your stomach or digestion;
  • hypocalcemia;
  • a dental problem (you may need a dental exam before you begin taking Lozostun);
  • kidney disease; or
  • any condition that makes it hard for your body to absorb nutrients from food (malabsorption).

The effervescent tablet contains a lot of sodium. Tell your doctor if you are on a low-salt diet before using this form of Lozostun.

In rare cases, this medicine may cause bone loss (osteonecrosis) in the jaw. Symptoms include jaw pain or numbness, red or swollen gums, loose teeth, or slow healing after dental work. The longer you use Lozostun, the more likely you are to develop this condition.

Osteonecrosis of the jaw may be more likely if you have cancer or received chemotherapy, radiation, or steroids. Other risk factors include blood clotting disorders, anemia (low red blood cells), and a pre existing dental problem.

Talk with your doctor about the risks and benefits of using this medication.

It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

It is not known whether Lozostun passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

How does this medication work? What will it do for me?

Lozostun belongs to a family of medications known as bisphosphonates. It is used to treat and prevent osteoporosis for postmenopausal women. It is also used to treat osteoporosis for men.

Lozostun may also be used to treat and prevent steroid-induced osteoporosis for men and women (osteoporosis caused by taking corticosteroids such as prednisone for long periods of time). It may also be used to treat Paget's disease of the bone for both men and women.

Lozostun increases the thickness of bone (bone mineral density) by slowing down the cells that usually break down bone (osteoclasts). This allows the cells that build bone (osteoblasts) to work more efficiently. By making bones stronger, Lozostun can help to reduce the incidence of osteoporosis-related fractures.

This medication may be available under multiple brand names and/or in several different forms. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here. As well, some forms of this medication may not be used for all of the conditions discussed here.

Your doctor may have suggested this medication for conditions other than those listed in these drug information articles. If you have not discussed this with your doctor or are not sure why you are taking this medication, speak to your doctor. Do not stop taking this medication without consulting your doctor.

Do not give this medication to anyone else, even if they have the same symptoms as you do. It can be harmful for people to take this medication if their doctor has not prescribed it.

© Copyright 2017-2020 - rootsdentclinic.com - We Care About You!